{"id":1773,"date":"2023-10-04T12:30:38","date_gmt":"2023-10-04T12:30:38","guid":{"rendered":"https:\/\/kidneycancercanada-beta.ubmepsilon.com\/mise-a-jour-a-la-liste-des-essais-cliniques\/"},"modified":"2026-03-31T15:33:56","modified_gmt":"2026-03-31T15:33:56","slug":"updates-to-the-clinical-trials-list-2","status":"publish","type":"post","link":"https:\/\/kidneycancercanada-beta.ubmepsilon.com\/fr\/updates-to-the-clinical-trials-list-2\/","title":{"rendered":"Mise \u00e0 jour \u00e0 la liste des essais cliniques"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column][vc_empty_space][vc_column_text]<strong>ESSAIS CLINIQUES POUR LES PATIENTS QUI N\u2019ONT PAS EU DE TRAITEMENTS M\u00c9DICAMENTEUX ANT\u00c9RIEURS<\/strong><\/p>\n<ul>\n<li><a href=\"\/trial\/nct05909995\/\">Une \u00e9tude sur l\u2019INCB 99280 en combinaison avec l\u2019ipilimumab chez des patients atteints d\u2019un cancer du rein avanc\u00e9<\/a><\/li>\n<\/ul>\n<p>[\/vc_column_text][vc_column_text]<\/p>\n<ul>\n<li><a href=\"\/trial\/nct05086692\/\">Une \u00e9tude du MDNA11 en monoth\u00e9rapie ou en combinaison avec le pembrolizumab chez des patients atteints d\u2019un cancer du rein avanc\u00e9<\/a><\/li>\n<\/ul>\n<p>[\/vc_column_text][vc_empty_space][vc_column_text]<strong>ESSAIS CLINIQUES POUR LES PATIENTS QUI ONT RE\u00c7U UN TRAITEMENT M\u00c9DICAMENTEUX ANT\u00c9RIEUR<\/strong><\/p>\n<ul>\n<li><a href=\"\/trial\/nct05199272\/\">Une \u00e9tude du 23ME-00610 chez des patients atteints d\u2019un cancer du rein avanc\u00e9<\/a><\/li>\n<\/ul>\n<p>[\/vc_column_text][vc_column_text]<\/p>\n<ul>\n<li><a href=\"\/trial\/nct04895709\/\">Une \u00e9tude du BMS 986340 en monoth\u00e9rapie ou en combinaison avec le nivolumab chez des patients atteints d\u2019un cancer du rein avanc\u00e9<\/a><\/li>\n<\/ul>\n<p>[\/vc_column_text][vc_column_text]<\/p>\n<ul>\n<li><a href=\"\/trial\/nct05277051\/\">Une \u00e9tude sur le GSK4381562 en monoth\u00e9rapie, en combinaison avec le dostarlimab, ou avec le dostarlimab + le GSK4428859A chez des patients atteints d\u2019un cancer du rein avanc\u00e9<\/a><\/li>\n<\/ul>\n<p>[\/vc_column_text][vc_column_text]<\/p>\n<ul>\n<li><a href=\"\/trial\/nct05544929\/\">Une \u00e9tude sur le KFA115 en monoth\u00e9rapie ou en combinaison avec le tislelizumab chez des patients atteints d\u2019un cancer du rein avanc\u00e9<\/a><\/li>\n<\/ul>\n<p>[\/vc_column_text][vc_column_text]<\/p>\n<ul>\n<li><a href=\"\/trial\/nct05086692\/\">Une \u00e9tude du MDNA11 en monoth\u00e9rapie ou en combinaison avec le pembrolizumab chez des patients atteints d\u2019un cancer du rein avanc\u00e9<\/a><\/li>\n<\/ul>\n<p>[\/vc_column_text][vc_empty_space][vc_empty_space][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_empty_space][vc_column_text]ESSAIS CLINIQUES POUR LES PATIENTS QUI N\u2019ONT PAS EU DE TRAITEMENTS M\u00c9DICAMENTEUX ANT\u00c9RIEURS Une \u00e9tude sur l\u2019INCB 99280 en combinaison avec l\u2019ipilimumab chez des patients atteints d\u2019un cancer du rein avanc\u00e9 [\/vc_column_text][vc_column_text] Une \u00e9tude du MDNA11 en monoth\u00e9rapie ou en combinaison avec le pembrolizumab chez des patients atteints d\u2019un cancer du rein avanc\u00e9 [\/vc_column_text][vc_empty_space][vc_column_text]ESSAIS CLINIQUES [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1107,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[19],"tags":[],"year-of-the-new":[54],"class_list":["post-1773","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-non-classifiee","year-of-the-new-54"],"_links":{"self":[{"href":"https:\/\/kidneycancercanada-beta.ubmepsilon.com\/fr\/wp-json\/wp\/v2\/posts\/1773","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneycancercanada-beta.ubmepsilon.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneycancercanada-beta.ubmepsilon.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneycancercanada-beta.ubmepsilon.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneycancercanada-beta.ubmepsilon.com\/fr\/wp-json\/wp\/v2\/comments?post=1773"}],"version-history":[{"count":1,"href":"https:\/\/kidneycancercanada-beta.ubmepsilon.com\/fr\/wp-json\/wp\/v2\/posts\/1773\/revisions"}],"predecessor-version":[{"id":1774,"href":"https:\/\/kidneycancercanada-beta.ubmepsilon.com\/fr\/wp-json\/wp\/v2\/posts\/1773\/revisions\/1774"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kidneycancercanada-beta.ubmepsilon.com\/fr\/wp-json\/wp\/v2\/media\/1107"}],"wp:attachment":[{"href":"https:\/\/kidneycancercanada-beta.ubmepsilon.com\/fr\/wp-json\/wp\/v2\/media?parent=1773"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneycancercanada-beta.ubmepsilon.com\/fr\/wp-json\/wp\/v2\/categories?post=1773"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneycancercanada-beta.ubmepsilon.com\/fr\/wp-json\/wp\/v2\/tags?post=1773"},{"taxonomy":"year-of-the-new","embeddable":true,"href":"https:\/\/kidneycancercanada-beta.ubmepsilon.com\/fr\/wp-json\/wp\/v2\/year-of-the-new?post=1773"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}